Actitrexx
The AI engine Fit Assessment
BetaThe company will be attending the 2024 Health Tech Forward Event
Blurb
ActiTrexx GmbH is a stem cell transplantation center that offers curative and cellular therapies.
HQ Location
Germany
Founded
2020
Employees
11 - 50
Total funding raised
$4.23M
Last Funding Event
Series A, $4.23M, March 2, 2021
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
Developer of a cell therapy technology designed for the treatment of patients after a stem cell transplant to prevent rejection reactions. The company's technology focuses on the development of clinical testing of cell therapeutics for the suppression of transplant rejection and autoimmunity and the portfolio of cell therapy, enabling patients to prevent the fatal consequences of rejection, significantly improving their quality of life, and also opening up to many therapy options.